Differences in classification of COPD patients into risk groups A-D: a cross-sectional study by unknown
Zogg et al. BMC Research Notes 2014, 7:562
http://www.biomedcentral.com/1756-0500/7/562RESEARCH ARTICLE Open AccessDifferences in classification of COPD patients into
risk groups A-D: a cross-sectional study
Stefanie Zogg1,3*†, Selina Dürr1†, David Miedinger1,2, Esther Helen Steveling2, Sabrina Maier1 and Jörg Daniel Leuppi1,2Abstract
Background: The Global Initiative for Chronic Obstructive Lung Disease proposed in 2011 a new system to classify
chronic obstructive pulmonary disease (COPD) patients into risk groups A-D, which considers symptoms and future
exacerbation risk to grade disease severity. The aim of this study was to investigate the agreement between COPD
risk group classifications using COPD assessment test (CAT) or modified Medical Research Council (mMRC) and
severity grades or past-year exacerbations. Furthermore, physical activity across risk groups was examined.
Methods: 87 patients with stable COPD were classified into risk groups A-D. CAT and mMRC were completed.
Severity grades I-IV were determined using spirometry and the number of past-year exacerbations was recorded. To
test the interrater agreement, Cohen’s Kappa was calculated. Daily physical activity was measured by the SenseWear
Mini armband.
Results: Using CAT, 65.5% of patients were in high-symptom groups (B and D). With mMRC, only 37.9% were in
B and D. Using severity grades, 20.7% of patients were in high-exacerbation risk groups (C and D). With past-year
exacerbations, 9.2% were in C and D. Interrater agreement between CAT and mMRC (κ = 0.21) and between severity
grades and past-year exacerbations (κ = 0.31) was fair. Daily steps were reduced in risk groups B and C + D compared
to A (p < 0.01), using either classification.
Conclusions: When classifying COPD patients into risk groups A-D, the use of CAT or mMRC and severity grades or
past-year exacerbations does not provide equal results. Daily steps decreased with increasing COPD risk groups.
Keywords: Chronic obstructive pulmonary disease, COPD assessment test, COPD risk groups, COPD severity grades,
Exacerbations, Modified Medical Research Council dyspnea scale, New GOLD 2011 classificationBackground
Chronic obstructive pulmonary disease (COPD) is one of
the leading causes of mortality in most countries [1].
Based on the Swiss COPD cohort, 23-25% of patients with
COPD experienced exacerbations requiring pharmaco-
logical treatment within one year [2-5]. While conven-
tional COPD classification was mainly based on airflow
limitation, the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) now recommends considering
symptoms and exacerbation risk to grade disease severity
into risk groups A-D (Figure 1). Symptoms are assessed
by COPD assessment test (CAT) or modified Medical* Correspondence: stefanie.zogg@ksbl.ch
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mMRC ≥2 indicate high impact of symptoms (risk groups
B and D). Exacerbation risk is determined by the degree of
airflow limitation using spirometry-based severity grades
I-IV or by the number of exacerbations in the previous
12 months. Patients in severity grades III-IV and those
with ≥2 past-year exacerbations have a high exacerbation
risk (risk groups C and D) [1].
Until now, there is little evidence concerning the
agreement of these components determining the new
COPD risk groups. Previous studies [6,7] have shown that
the threshold of CAT score ≥10 might not be equivalent
to the threshold of mMRC score ≥2 for categorizing
patients into low or high symptom groups. However, no
study has investigated the agreement between risk groups
classified either by severity grades I-IV or the number of
exacerbations in the previous 12 months to determinetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Schematic illustration of the COPD classification
into risk groups A-D. CAT, COPD assessment test; COPD, chronic
obstructive pulmonary disease; GOLD, Global Initiative for Chronic
Obstructive Lung Disease; mMRC, modified Medical Research
Council. Patient group A: Low risk, less symptoms. Patient group B:
Low risk, more symptoms. Patient group C: High risk, less symptoms.
Patient group D: High risk, more symptoms [1].
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that regarding mortality, the overall trend was that low
lung function was a stronger predictor of death than
exacerbation history.
In patients with COPD, physical activity is related to
pulmonary limitations [9-11], extrapulmonary effects [12],
health-related quality of life [13] and individual lifestyle
[14]. Furthermore, regular physical activity was found to
reduce the risk of hospitalisations and exacerbations, and
to modify smoking-related lung function decline [15,16].
Moreover, physical activity level (PAL), daily steps and
6-min walk distance (6MWD) decline with increasing
severity grades I-IV [9]. However, differences in physical
activity across the new COPD risk groups A-D have not
been investigated so far.
The primary aim of this study was to analyse the inter-
rater agreement between COPD risk group classifications
using CAT or mMRC, as well as using severity grades I-IV
or past-year exacerbations. We hypothesized that all
classifications yield similar risk group assignments. The
secondary objective was to examine daily physical activity
across COPD risk groups based on CAT or mMRC,
and severity grades I-IV or past-year exacerbations. Fur-
thermore, correlations between physical activity parame-
ters and CAT score, mMRC score, number of past-year
exacerbations and forced expiratory volume in 1 s in %
of predicted (FEV1%predicted) were investigated.Methods
Study subjects
From July 2011 to January 2012, patients with COPD were
recruited from a patient-file database of the University
Hospital Basel, Switzerland. Exclusion criteria were COPD
exacerbations within the last 30 days and pregnancy.
Ninety-one out of 248 approached patients agreed to par-
ticipate (Figure 2). Reasons for refusal were: no interest,
bad general condition, current hospitalisation and insuffi-
cient knowledge of the German language. Eighty-seven
clinically stable COPD patients were finally investigated
and classified into risk groups A-D according to the revised
COPD GOLD guidelines 2011. The present investigation
was approved by the local ethics committee (EKBB,
163/11) and written informed consent was obtained
from all subjects.
Study design
In this cross-sectional study, the Swiss German version
of CAT and the mMRC dyspnea scale were administered
to the patients in order to assess symptoms and exertional
dyspnea, respectively. Then, spirometry was performed for
determining COPD severity grades. In addition, exacer-
bation history and several demographic factors were
recorded. Finally, patients were instructed to wear the
SenseWear Mini armband for the subsequent week in
order to quantify daily physical activity.
Methods
COPD assessment test
CAT is a short health status questionnaire developed to
provide a simple tool for assessing the impact of COPD
[17]. It consists of 8 items, each presented as semantic
6-point differential scale, providing a total score ranging
from 0–40 [17]. The content of CAT covers daily symp-
toms, such as cough, phlegm and chest tightness as well
as other manifestations of COPD like breathlessness going
up hills/stairs, activity limitation at home, confidence in
leaving home, sleep and energy [17].
Modified Medical Research Council dyspnea scale
The mMRC dyspnea scale is a modified version of the
original MRC dyspnea scale developed by Fletcher in
1952 [18]. It has more simplified statements and is based
on 5 stages of exertional dyspnea ranging from 0–4 [19].
Lung function
Spirometry was performed according to the guidelines of
the American Thoracic and European Respiratory Societies
[20]. The EasyOne spirometer (ndd Medizintechnik AG,
Zürich, Switzerland) was used to assess lung function
before and 15 min after inhalation of 200 μg fenoterol.
Severity of airflow limitation was classified according to
Figure 2 Flowchart of study subjects. *COPD was defined as post-bronchodilator FEV1/FVC ratio <0.70. COPD, chronic obstructive
pulmonary disease.
Zogg et al. BMC Research Notes 2014, 7:562 Page 3 of 8
http://www.biomedcentral.com/1756-0500/7/562the GOLD guidelines based on post-bronchodilator
FEV1%predicted [1].
Exacerbation history
The number of COPD exacerbations in the previous
12 months was determined by asking the patients and
consulting the hospital medical file. An exacerbation was
defined as a worsening of the subject’s condition beyond
normal day-to-day variations that required additional
treatment with oral or intravenous corticosteroids or
antibiotics [1].
Patients’ characteristics
Age, gender, height, weight, handedness, smoking status
(yes, no, never) and current medication were recorded.
Furthermore, the number of comorbidities was docu-
mented by accessing the hospital medical file.
Daily physical activity
Daily physical activity was measured by the SenseWear
Mini armband developed by Bodymedia (Pittsburgh,
Pennsylvania, USA) [21]. It integrates motion data from
a three-axis accelerometer along with several other
physiological sensors such as heat flux, skin temperature
and galvanic skin response [21]. In patients with COPD,
validity and reliability of the SenseWear armband were
established by Hill et al. [22].
Participants were instructed to wear the SenseWear
Mini armband on the left arm (triceps) for 7 consecutive
days, except during water-based activities. The patientswere told that the off-body duration of the armband
should not exceed 1 h a day. To ensure a standardized
procedure, the first and the last incomplete measurement
day, including the study visits, were not taken into account.
Therefore, the investigated measurement period was 5 days
(3 weekdays and 2 weekend days). Reliability of this assess-
ment period has been previously shown [23]. Patients with
a wearing time of less than 5 days and less than 12 hours
per day (from wake-up time to 12 hours after waking) were
excluded from analyses [24,25].
The physiological data collected by the armband’s
sensors were processed by specific algorithms available
in the software (professional software V.7.0, algorithm
V.2.2.4). Age, gender, height, weight, handedness and
smoking status were also considered in these calculations.
Patients’ average daily number of steps, active energy
expenditure (AEE), physical activity duration above 3 METs
(PA3) and physical activity level (PAL) were examined.
1 MET defined as metabolic equivalent and expressing
the energy cost of physical activity, corresponds to
3.5 ml/min/kg VO2 [20].
Missing data
In 2 patients, severity grades were determined with pre-
bronchodilator data. In these 2 patients, asthma was
excluded by asking the patients, if they had been pre-
viously diagnosed with asthma, and by looking at prior
diagnoses of asthma in the medical files. Furthermore,
the first 8 patients did not complete the mMRC dyspnea
scale and in 9 patients, SenseWear data were missing for 1
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corresponding analyses.
Statistical analysis
The main outcome measures were analysed using the
SPSS software package (version 19.0, IBM, Germany).
Significance was set at the 5% level. The Shapiro-Wilk test
was used to test, whether data were normally distributed.
Patients’ characteristics are presented as mean ± standard
deviation (SD) or number and percentage. To test the
interrater agreement between CAT and mMRC as well as
between severity grades and past-year exacerbations,
Cohen’s Kappa (κ) was calculated. Κ < 0.00 indicates “poor”,
0.00 ≤ κ ≤ 0.02 “slight”, 0.21 ≤ κ ≤ 0.40 “fair”, 0.41 ≤ κ ≤ 0.60
“moderate”, 0.61 ≤ κ ≤ 0.80 “substantial” and 0.81 ≤ κ ≤ 1.00
“perfect” agreement [26]. To analyse differences in demo-
graphic characteristics and physical activity across COPD
risk groups based on CAT or mMRC and severity grades
or past-year exacerbations, mean comparisons were per-
formed using One-Way ANOVA, Kruskal-Wallis test or
Chi-squared test, if appropriate. Risk groups C and D, both
indicating high exacerbation risk, were combined for statis-
tical analysis due to the small number of patients in these
subgroups. Furthermore, Pearson correlations were calcu-




Patients’ characteristics are presented in Table 1. Age
ranged from 44–90 yrs (mean age: 67.3 ± 9.6 yrs). 51 menTable 1 Characteristics of the 87 study participants
Variable n (%) or mean ± SD
Age [yrs] 67.3 ± 9.6
Male 51 (58.6)
Current smokers 41 (47.1)
BMI [kg/m2] 25.5 ± 5.4
CAT score 13.3 ± 7.2
mMRC score1 1.4 ± 0.9
Number of past-year exacerbations 0.4 ± 0.8
FEV1predicted [%]
2 69.1 ± 24.3
FEV1/FVC [%]
2 53.3 ± 13.8
Number of comorbidities 2.2 ± 2.1
Average daily steps3 4783.6 ± 3337.6
Average daily AEE [cal]3 443.6 ± 383.1
Average daily PA3 [min]
3 94.6 ± 84.0
Average daily PAL [METs]3 1.3 ± 0.3
BMI, body mass index; CAT, COPD assessment test; FEV1predicted, forced
expiratory volume in 1 s of predicted; FVC, forced vital capacity; MET,
metabolic equivalent; mMRC, modified Medical Research Council; PAL, physical
activity level; PA3, physical activity duration above 3 METs; SD, standard
deviation. 1(n = 79); 2(n = 85); 3(n = 78).and 36 women were investigated. Almost half of the
patients were current smokers, while 40 (46.0%) patients
had stopped smoking and only 6 (6.9%) patients had never
smoked in their life. The distribution of patients classified
into risk groups A-D differed according to the use of CAT
or mMRC and severity grades or past-year exacerbations
(Figure 3). With CAT, 57 (65.5%) patients were found to
be in high-symptom groups (B and D), compared to 33
(37.9%) patients using mMRC. Using severity grades I-IV,
18 (20.7%) patients were in high-exacerbation risk groups
(C and D). With past-year exacerbations, 8 (9.2%) patients
were in C and D.Interrater agreement
The interrater agreement between CAT and mMRC
was found to be fair (κ = 0.21). However, CAT and mMRC
showed a significant correlation (r = 0.45, p < 0.001).
Regarding severity grades and past-year exacerbations,
a fair interrater agreement (κ = 0.31) was detected, too.
FEV1%predicted and the number of past-year exacerba-
tions correlated with each other (r = −0.29, p = 0.004).Demographic characteristics and physical activity across
COPD risk groups
Demographic characteristics split by COPD risk groups
based on CAT or mMRC and severity grades or past-year
exacerbations are shown in Table 2. When comparing
gender, smoking status and comorbidities across COPD
risk groups, no significant differences were found. Basing
risk groups on CAT and past-year exacerbations, age was
higher in risk group A compared to B (70.4 ± 8.4 yrs vs.
64.7 ± 10.0 yrs, p = 0.029). Regarding the traditional
GOLD grades I-IV, significantly less men were found to
be in grade I compared to IV (p = 0.027), whereas all other
characteristics did not differ across severity grades.
Mean differences in physical activity across COPD risk
groups are presented in Table 3. Basing risk groups on
CAT and severity grades, steps were higher in risk group
A compared to B (p = 0.003) and C + D (p < 0.001), while
AEE showed a significant difference between A and B
(p = 0.007). Using mMRC and severity grades, only steps
were found to be reduced in risk group B (p = 0.001)
and C + D (p < 0.001) compared to A. Based on CAT
and past-year exacerbations, steps were higher in risk
group A compared to B (p = 0.001) and C +D (p = 0.002),
whereas AEE was different from risk group A to B
(p = 0.007). Using mMRC and past-year exacerbations,
steps were also higher in risk group A compared to B
(p = 0.001) and C + D (p = 0.002). Furthermore, only
steps were found to be significantly higher in GOLD
grade I (p = 0.001) and II (p = 0.004) compared to IV.
PA3 and PAL showed no significant differences across
all COPD classifications.
Figure 3 Distribution of the 87 patients across the 4 possibilities of COPD risk group classifications. CAT, COPD assessment test; mMRC,
modified Medical Research Council.
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Table 4 illustrates bivariate correlations between physical
activity parameters and CAT, mMRC, FEV1%predicted
and past-year exacerbations. CAT and mMRC showed a
significant relationship with all investigated SenseWear
activity parameters, whereas FEV1%predicted and the
number of past-year exacerbations were significantly
associated only with daily steps.
Discussion
The main findings of this study were that CAT and
mMRC, as well as severity grades I-IV and past-year
exacerbations showed only a fair agreement when they
were used to determine patients’ COPD risk groups
according to the new COPD GOLD guidelines. More-
over, daily steps differed significantly across risk groups
A-D, regardless of which parameters the risk groups
were composed.
The new COPD GOLD guidelines recommend two
alternatives for the assessment of symptoms and exacerba-
tion risk. Originally, CAT and mMRC, as well as severity
grades and past-year exacerbations were thought to
provide equivalent risk group classifications [1]. How-
ever, Jones et al. [6] and Kim et al. [7] have shown that
a CAT score ≥10 might not be equivalent to an mMRC
score ≥2, when classifying patients into low or highsymptom groups. To improve the interrater agreement,
they suggested using a cut-point of mMRC ≥1 [6,7].
The present investigation confirmed the fair agreement
between CAT and mMRC. Using CAT, more patients
were categorised into risk groups B and D with a high
impact of symptoms than using mMRC. Since CAT and
mMRC do not provide the same COPD risk group classifi-
cations, it may be favorable to restrict to one symptom
assessment tool. While CAT assesses the general health
status of COPD [17], mMRC was developed to measure
dyspnea [18]. A CAT score ≥10 has been shown to have a
significant impact on daily life in patients with COPD
[27]. Furthermore, patients with a CAT score ≥10 are
likely to be breathlessness on most days and get exhausted
easily [27]. Due to its comprehensiveness, CAT may be
preferred for classifying patients into COPD risk groups
A-D.
Based on severity grades, twice as many patients had a
high exacerbation risk compared to the use of past-year
exacerbations, when classifying patients into COPD risk
groups A-D. Despite the clear definition of an exacerba-
tion [28], it is still difficult to ensure a correct recording
of the exacerbation history. On the contrary, spirometry-
based severity grades represent an objective and reliable
measurement [1]. The direct comparison of these two
risk assessments might be difficult and could explain the
Table 2 Demographic characteristics across COPD risk groups A-D and GOLD grades I-IV
Variable Age [yrs] Male Number of comorbidities Current smokers
Classification N Mean ± SD N (%) Mean ± SD N (%)
CAT - Severity grades 87
A 29 70.2 ± 8.5 15 (51.7) 2.1 ± 2.6 13 (44.8)
B 40 65.6 ± 10.6 21 (52.5) 2.5 ± 1.9 22 (55.0)
C + D 18 66.2 ± 8.4 15 (83.3) 1.9 ± 1.6 6 (33.3)
mMRC – Severity grades 79
A 42 66.2 ± 9.4 21 (50.0) 2.1 ± 2.2 23 (54.8)
B 20 69.9 ± 12.0 11 (55.0) 2.6 ± 1.7 10 (50.0)
C + D 17 66.1 ± 8.6 14 (82.4) 1.8 ± 1.6 6 (35.3)
CAT - Exacerbations 87
A 30 70.4 ± 8.4 16 (53.3) 2.1 ± 2.6 13 (43.3)
B 48 64.7 ± 10.0 30 (62.5) 2.4 ± 1.8 24 (50.0)
C + D 9 70.7 ± 7.9 5 (55.6) 2.0 ± 1.9 4 (44.4)
mMRC - Exacerbations 79
A 48 65.8 ± 9.2 26 (54.2) 2.1 ± 2.1 20 (41.7)
B 22 68.5 ± 12.1 15 (68.2) 2.4 ± 1.6 9 (40.9)
C + D 9 70.7 ± 7.9 5 (55.6) 2.0 ± 1.9 4 (44.4)
GOLD grades 87
I 23 67.5 ± 10.2 9 (39.1) 2.1 ± 2.5 11 (47.8)
II 46 67.6 ± 10.0 27 (58.7) 2.5 ± 2.0 24 (52.2)
III 12 66.2 ± 9.2 9 (75.0) 1.5 ± 1.4 6 (50.0)
IV 6 66.2 ± 7.1 6 (100.0) 2.7 ± 1.9 0 (0.0)
CAT, COPD assessment test; COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; mMRC, modified Medical
Research Council; SD, standard deviation.
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reliability, spirometry-based severity grades may be pre-
ferred for COPD classification into risk groups A-D.
Daily steps better distinguished patients with COPD
across the new risk groups than AEE, PAL and PA3.
This finding is underlined by the fact that daily steps
correlated with all components (CAT, mMRC, FEV1%
predicted and past-year exacerbations) of the new COPD
risk groups. Furthermore, daily steps might reflect patient’s
mobility and lifestyle better than PA3 and PAL. Engström
et al. [14] could show that patients with COPD differed
from healthy controls in both, walking activities as well as
mobility. Previous studies [10,29] confirmed that daily steps
diminished with increasing COPD severity grades. In
contrast, Watz et al. [10] showed that also PA3 and PAL
decreased with increasing COPD severity grades I-IV,
but no significant difference was found between severity
grades I and II. In the present study, only few patients
were in risk groups C and D, whereas Watz et al. [10]
had evenly distributed number of patients in all severity
grades. These findings suggest that PA3 and PAL may
not differ between mild COPD severity grades I and II
and risk groups A and B.Clinical implications
The new COPD GOLD guidelines propose specific therapy
according to risk group classifications. Misclassification
due to the use of CAT ≥10 or mMRC ≥2 and severity
grades III-IV or ≥2 past-year exacerbations could lead to
inconsistent management and treatment of the affected
COPD patients. Therefore, it might be advantageous to
use only one tool to assess symptoms and exacerbation
risk, respectively.
As daily steps showed the strongest association with
the disease, pulmonary rehabilitation could use daily
steps to assess functional status in patients with COPD.
Strengths and limitations
In this study, components of the new combined COPD
risk groups were assessed in a standardized way by reliable
assessment tools. No remarkable differences in demo-
graphic characteristics across risk groups were detected
using either classification.
However, the sample size and the number of patients
with high exacerbation risk were limited. Therefore, the
present study was not representative for COPD risk groups
C and D and the comparison between exacerbation risk
Table 3 Means of steps, AEE, PA3 and PAL across COPD risk groups A-D and GOLD grades I-IV
Variable Steps AEE [cal] PA3 [min] PAL [METs]
Classification N Mean ± SD Mean ± SD Mean ± SD Mean ± SD
CAT - Severity grades 78
A 27 6763.1 ± 4005.1 599.3 ± 477.0 116.3 ± 89.9 1.4 ± 0.3
B 36 4152.6 ± 2571.9 337.2 ± 297.3 76.5 ± 76.9 1.3 ± 0.3
C + D 15 2732.8 ± 1362.5 418.9 ± 295.4 99.1 ± 85.4 1.4 ± 0.3
mMRC – Severity grades 71
A 40 5971.3 ± 3302.5 460.4 ± 399.1 98.2 ± 84.0 1.4 ± 0.3
B 17 3633.8 ± 2996.1 376.3 ± 343.9 79.9 ± 88.4 1.3 ± 0.3
C + D 14 2811.4 ± 1378.2 426.5 ± 305.0 100.9 ± 88.3 1.4 ± 0.3
CAT - Exacerbations 78
A 27 6763.1 ± 4005.1 599.3 ± 477.0 116.3 ± 90.0 1.4 ± 0.3
B 42 3923.7 ± 2488.5 344.0 ± 288.8 77.7 ± 76.4 1.3 ± 0.3
C + D 9 2858.3 ± 1439.1 441.3 ± 334.7 108.4 ± 92.1 1.4 ± 0.3
mMRC - Exacerbations 71
A 43 5794.4 ± 3247.1 469.2 ± 391.5 97.7 ± 84.8 1.4 ± 0.3
B 19 3426.5 ± 2937.7 349.3 ± 322.7 80.2 ± 84.9 1.3 ± 0.3
C + D 9 2858.3 ± 1439.1 441.3 ± 334.7 108.4 ± 92.1 1.4 ± 0.3
GOLD grades 78
I 22 6191.8 ± 3985.2 496.9 ± 434.8 96.1 ± 97.1 1.3 ± 0.3
II 41 4778.3 ± 3128.5 424.1 ± 388.0 92.1 ± 78.0 1.3 ± 0.3
III 9 3358.1 ± 1436.3 462.1 ± 345.5 116.4 ± 103.2 1.4 ± 0.3
IV 6 1794.8 ± 371.2 354.0 ± 211.7 73.0 ± 44.9 1.3 ± 0.1
AEE, active energy expenditure; CAT, COPD assessment test; COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung
Disease; MET, metabolic equivalent; mMRC, modified Medical Research Council; PAL, physical activity level; PA3, physical activity duration above 3 METs; SD,
standard deviation.
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biased. This could have led to the weak agreement between
these two parameters. Further research with a larger
sample size is needed to clarify this issue. Furthermore,
the SenseWear Mini armband was found to underestimate
the number of daily steps at slow walking speeds in
patients with COPD [30]. The present analysis still
found a significant association between daily steps and
disease severity, which needs to be confirmed by further
studies. Another limitation was the cross-sectional study
design, which does not allow assessment of disease
changes over time.Table 4 Bivariate correlations of steps, AEE, PA3 and PAL with
Variable CAT score mMRC score1
r p r p
Steps −0.37 <0.001 −0.51 <0.00
AEE [cal] −0.24 0.016 −0.30 0.00
PA3 [min] −0.25 0.014 −0.27 0.01
PAL [METs] −0.18 0.058 −0.21 0.03
AEE, active energy expenditure; CAT, COPD assessment test; FEV1%predicted, forced
modified Medical Research Council; p, probability level; PAL, physical activity level;
Significant p-values are highlighted in bold. 1(n = 71); 2(n = 77).Conclusions
The present analyses showed that the use of CAT or
mMRC and severity grades I-IV or past-year exacerba-
tions did not provide the same results when classifying
COPD patients into risk groups A-D. These findings
suggest that the new GOLD 2011 classification into risk
groups A-D may require modification. Daily steps were
significantly reduced in severe COPD risk groups com-
pared to mild ones, while AEE, PA3 and PAL showed no
or just a weak association with disease severity. Further
investigation with a larger sample size is required to
confirm our results.CAT, mMRC, FEV1%predicted and exacerbations (n = 78)
Exacerbations FEV1%predicted
2
r p r p
1 −0.23 0.021 0.42 <0.001
6 −0.05 0.332 0.13 0.136
1 0.02 0.430 0.05 0.337
8 0.02 0.441 0.02 0.449
expiratory volume in 1 s in % of predicted; MET, metabolic equivalent; mMRC,
PA3, physical activity duration above 3 METs; r, correlation coefficient.
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